Ang Li

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Leora Horn, David R. Spigel, Everett E. Vokes et al. · Journal of Clinical Oncology · 2017 · 857 citations · Full text

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

Scott Gettinger, Leora Horn, David M. Jackman et al. · Journal of Clinical Oncology · 2018 · 731 citations

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Hossein Borghaei, Scott Gettinger, Everett E. Vokes et al. · Journal of Clinical Oncology · 2021 · 614 citations · Full text

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

Scott Antonia, Hossein Borghaei, Suresh S. Ramalingam et al. · The Lancet Oncology · 2019 · 361 citations · Full text

Oncology, Four-year Survival, Immune Checkpoint Inhibitor +5

Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China

Zhigang Ren, Jianwen Jiang, Haiyang Xie et al. · Oncotarget · 2017 · 227 citations · Full text